Time-resolved fluorescence immunoassay (TRFIA) for the simultaneous detection of hs-CRP and lipoprotein(a) in serum

被引:9
作者
Ma, Hongyan [1 ]
Mao, Qian [1 ]
Zhu, Yanbin [1 ]
Cong, Chunli [1 ]
Zheng, Shiyu [1 ]
Zhang, Qi [1 ]
Chen, Cuicui [2 ]
Li, Laiqing [2 ]
机构
[1] Beihua Univ, Dept Cardiol, Affiliated Hosp, Jilin, Jilin, Peoples R China
[2] Guangzhou Youdi Biotechnol Co Ltd, 3 Juquan Rd, Guangzhou 510663, Peoples R China
关键词
atherosclerosis; biomarker; high-sensitivity C-reactive protein; lipoprotein(a); serum; time-resolved fluorescence immunoassay; C-REACTIVE PROTEIN; ATHEROSCLEROSIS; MARKERS; INFLAMMATION;
D O I
10.1002/bab.2310
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Elevated serum high-sensitivity C-reactive protein (hs-CRP) and lipoprotein(a) (Lp(a)) levels are associated with the development of native coronary atherosclerosis. We aimed to establish a new method for the simultaneous detection of hs-CRP and Lp(a) to predict the development of atherosclerosis. A one- step time-resolved fluorescence immunoassay (TRFIA) with europium(III) (Eu3+) or samarium(III) (Sm3+) labelswas established, and the performance of this TRFIA (in terms of sensitivity, specificity, accuracy, and cutoff values) was evaluated using clinical serum samples and comparedwith those of registered kits. The sensitivity was 0.052 mu g/ml for hs-CRP and 0.64 mu g/ml for Lp(a). The intra-assay and inter-assay cross-reactivities (CVs) were very low, ranging from 2.05% to 4.67% for hs- CRP and from 2.42% to 6.43% for Lp(a). The CVs were very low (<0.34% and <2.65%, respectively) with five interferents. Additionally, there was a high Pearson coefficient between the present TRFIA method and the registered kits (R-2 = 0.9967 and 0.9906, respectively). These data indicate that this study developed a TRFIA method that can be used for the quantitative detection of hs- CRP and Lp(a) in serum with high sensitivity, specificity, and accuracy. This TRFIA provides a new method for predicting the development of atherosclerosis.
引用
收藏
页码:2617 / 2623
页数:7
相关论文
共 21 条
[1]   High lipoprotein (a), diabetes, and the extent of symptomatic intracranial atherosclerosis [J].
Arenillas, JF ;
Molina, CA ;
Chacón, P ;
Rovira, A ;
Montaner, J ;
Coscojuela, P ;
Sánchez, E ;
Quintana, M ;
Alvarez-Sabín, J .
NEUROLOGY, 2004, 63 (01) :27-32
[2]   Lipid and inflammatory markers for the prediction of coronary artery disease: A multi-marker approach [J].
Bogavac-Stanojevic, Natasa ;
Jelic-Ivanovic, Zorana ;
Spasojevic-Kahmanovska, Vesna ;
Spasic, Slavica ;
Kalimanovska-Ostric, Dimitra .
CLINICAL BIOCHEMISTRY, 2007, 40 (13-14) :1000-1006
[3]   European Atherosclerosis Society Screening Recommendations for Lipoprotein(a) and High-Sensitivity C-Reactive Protein: Double Standard or Failure of Evidence-Based Medicine? [J].
Goldhaber, Samuel Z. .
CLINICAL CHEMISTRY, 2010, 56 (10) :1544-1546
[4]   Localization of tissue transglutaminase in human carotid and coronary artery atherosclerosis: Implications for plaque stability and progression [J].
Haroon, ZA ;
Wannenburg, T ;
Gupta, M ;
Greenberg, CS ;
Wallin, R ;
Sane, DC .
LABORATORY INVESTIGATION, 2001, 81 (01) :83-93
[5]   C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis [J].
Hashimoto, H ;
Kitagawa, K ;
Hougaku, H ;
Shimizu, Y ;
Sakaguchi, M ;
Nagai, Y ;
Iyama, S ;
Yamanishi, H ;
Matsumoto, M ;
Hori, M .
CIRCULATION, 2001, 104 (01) :63-67
[6]   ELEVATED LIPOPROTEIN(A) AND HS-CRP AS A POOR PROGNOSTIC MARKER IN PATIENTS WITH CORONARY ARTERY DISEASE [J].
Kwon, S. ;
Yoon, Y. ;
Lee, B. ;
Hong, B. ;
Kwon, H. .
ATHEROSCLEROSIS, 2015, 241 (01) :E20-E20
[7]  
Larsson PT, 2005, INT ANGIOL, V24, P43
[8]   A time-resolved fluoroimmunoassay to assay the rabies virus glycoprotein: application for estimation of human rabies vaccine potency [J].
Lin, Guanfeng ;
Chen, Shaolang ;
Zhao, Hui ;
Liang, Junyu ;
Deng, Qiaoting ;
Liang, Rongliang ;
Guo, Xinxin ;
Chen, Zhenhua ;
Chen, Baihong ;
Liu, Tiancai ;
Wu, Yingsong .
SCIENTIFIC REPORTS, 2017, 7
[9]   Xuezhikang decreases serum lipoprotein(a) and C-reactive protein concentrations in patients with coronary heart disease [J].
Liu, L ;
Zhao, SP ;
Cheng, YC ;
Li, YL .
CLINICAL CHEMISTRY, 2003, 49 (08) :1347-1352
[10]   Serum lipids, lipoprotein(a) level, and apolipoprotein(a) isoforms as prognostic markers in patients with coronary heart disease [J].
Lundstam, U ;
Herlitz, J ;
Karlsson, T ;
Lindén, T ;
Wiklund, O .
JOURNAL OF INTERNAL MEDICINE, 2002, 251 (02) :111-118